/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $61.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The biotechnology company is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Friday, Aug. 1.
Ahead of the event, analysts expect REGN to report a profit of $6.23 per share on a diluted basis, down 38.3% from $10.10 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
For the full year, analysts expect REGN to report EPS of $28.27, down 26.8% from $38.62 in fiscal 2024. However, its EPS is expected to rise 9.3% year over year to $30.90 in fiscal 2026.
REGN stock has significantly underperformed the S&P 500 Index’s ($SPX) 17.3% gains over the past 52 weeks, with shares down 46.8% during this period. Similarly, it considerably underperformed the Health Care Select Sector SPDR Fund’s (XLV) 9.4% dip over the same time frame.
REGN is facing challenges due to declining sales of its key drug Eylea, amid increased competition from Roche Holding AG’s (RHHBY) Vabysmo and potential biosimilars. The company's partnership with Sanofi (SNY) has also seen setbacks, including mixed results from late-stage studies on itepekimab. These factors have negatively impacted REGN's stock performance, and the company has a tough road ahead in diversifying its revenue streams and offsetting the decline in Eylea sales.
On Apr. 29, REGN shares closed down by 6.9% after reporting its Q1 results. Its adjusted EPS of $8.22 fell short of Wall Street's expectations of $8.43. The company’s revenue was $3 billion, falling short of Wall Street forecasts of $3.3 billion.
Analysts’ consensus opinion on REGN stock is reasonably bullish, with an overall “Moderate Buy” rating. Out of 25 analysts covering the stock, 17 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” six give a “Hold,” and one recommends a “Moderate Sell.” REGN’s average analyst price target is $737.71, indicating a potential upside of 30.7% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
